Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Artios Pharma Ltd
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Hospital, Caen
National Cancer Institute (NCI)
Frontier Medicines Corporation
Cedars-Sinai Medical Center
Boehringer Ingelheim
National Cancer Institute (NCI)
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Harbinger Health
BioNTech SE
University of Southern California
Boehringer Ingelheim
AstraZeneca
Criterium, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
University of Southern California
West China Hospital
Tongji Hospital
Seagen Inc.
Genmab
Centre Hospitalier Universitaire de Besancon
Origin Sciences
Seagen Inc.
Incyte Corporation
Incyte Corporation
University Hospital, Bordeaux
Hoffmann-La Roche
Jules Bordet Institute
Centre Oscar Lambret
Centre Oscar Lambret
Centre Oscar Lambret